Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Madrigal Pharmaceuticals gains FDA approval for NASH medicine Rezdiffra

Madrigal Pharmaceuticals achieved FDA approval for Rezdiffra, focusing on market leadership and patient services.
Sales expected to be back-end loaded in 2024, with varying prescription dynamics and affordability considerations.
Company confident in revenue consensus but hasn't provided specific numbers, creating uncertainty for investors.
Emphasis on high unmet need, early positive feedback, and comprehensive patient support services.

Madrigal Pharmaceuticals excels in Q2 with Rezdiffra launch success

Madrigal Pharmaceuticals demonstrated strong financial performance and market acceptance of Rezdiffra in Q2 2024.
The company faces challenges in educating stakeholders and managing operational aspects of expansion.
Opportunities lie in global expansion, new market segments, and continued growth in sales and brand recognition.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on March 2000 and is headquartered in West Conshohocken, PA.

On Tuesday, Madrigal won an important regulatory designation from the FDA for its NASH candidate. The biotech got another boost from the ongoing buyout bonanza in biotech.

Why Madrigal Pharmaceuticals Stock Gained 20% This Week

CRISPR Therapeutics

Legend Biotech

Vaxcyte

Revolution Medicines

Ventyx Biosciences

Western Alliance Bancorporation

Where is the current bull market? All indications would be that it's in biotech!

Where Is The Current Bull Market? Scan Of Stocks Gaining Over 20% Over The Past Week Almost Exclusively Yields Biotech Names

Madrigal Pharmaceuticals (MDGL) gains on receiving Breakthrough Therapy designation from the FDA for resmetirom.

Madrigal (MDGL) Gains on NASH Treatment's Breakthrough Therapy Tag

Madrigal snagged a breakthrough therapy designation for its liver disease treatment on Tuesday and MDGL stock surged closer to a buy point. The post Why Top 1% Biotech Madrigal Pharmaceuticals Just Surged Closer To A Breakout appeared first on Investor's Business Daily.

Why Top 1% Biotech Madrigal Pharmaceuticals Just Surged Closer To A Breakout

Alnylam Pharmaceuticals

Apellis Pharma

argenx

Ascendis Pharma

BioMarin Pharmaceutical

Amicus Therapeutics

Horizon Pharma

Sarepta Therapeutics

United Therapeutics

Avoro Capital Advisors (formerly known as venBio Select Advisor) is a global life sciences investment firm that focuses on emerging biotechnology companies.

These Are the Top 10 Holdings of Avoro Capital Advisors

Medical Properties Trust

NVIDIA

Tesla

Viking Therapeutics

Several key themes are emerging in the stock investing landscape. These five stocks are poised to benefit from these powerful trends.

5 Best Stocks to Buy in April

Akero Therapeutics Inc

89bio Inc

Intercept Pharma

Eli Lilly

Novo Nordisk

Pfizer

Terns Pharmaceuticals

NASH, or nonalcoholic steatohepatitis, is a liver inflammatory disease that can progress to fibrosis and cirrhosis. NASH is now the second leading cause of liver transplantation, and the US patient population is forecast to increase from 16 million in 2015 to 27 million in 2030.

A Perfect Storm In Pharmacotherapy: The Opportunity To Invest In NASH

The stock market tends to be efficient at pricing equities, but not always. Experimental drug developers in particular have often turned out to be wildly mispriced by skeptical investors.

1 Incredible Growth Stock That Could Turn $200,000 Into $1 Million by 2030

Vertex Pharmaceuticals

These top growth stocks sport premium valuations for a very good reason.

3 Incredible Growth Stocks to Buy if the Market Dips

These two NASH drugmakers have a lot of room to run.

2 Surging Healthcare Stocks That Are Still Worth Buying

CONSHOHOCKEN, Pa., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today provides a summary of corporate updates and reports fourth quarter and full year 2022 financial results.

Madrigal Pharmaceuticals Provides Corporate Updates and Reports 2022 Fourth Quarter and Full Year Financial Results

CONSHOHOCKEN, Pa., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), announced today its management team will participate in three upcoming investor conferences:

Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences

Affirm

AppLovin Corp

Guardant Health Inc

Immunovant Inc

Maxar Technologies

Rogers

Rumble Inc

Prometheus Biosciences

Mid-cap stocks are proving to be an attractive investment option over the past few years.

5 Best and Worst Performing Mid-Cap Stocks in Q4 2022

As everyone knows, Madrigal outperformed expectations with outstanding results stemming from Maestro NASH study. I assess Madrigal's current valuation, based on future sales potential of resmetirom in the US as a basis.

Madrigal: Fairly Valued At These Levels

McKesson

These healthcare stocks have a lot going for them in the new year.

3 Top Healthcare Stocks to Buy for January

AMC Entertainment

Global Business Travel Group I

Mirati Therapeutics

Intellia Therapeutics

Mid-cap companies are fast-growing, young companies that are not as volatile as small-cap and not as stable as large-cap companies.

These Were the 5 Best and Worst Performing Mid-Cap Stocks in Dec 2022

CONSHOHOCKEN, Pa., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced additional results from the pivotal Phase 3 MAESTRO-NASH biopsy clinical trial of resmetirom, a liver-directed selective thyroid hormone receptor agonist. The new MAESTRO-NASH data are being presented at the NASH-TAG Conference, taking place from January 5-7, 2023 in Park City, Utah.

Madrigal Announces Additional Positive Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH with Liver Fibrosis

Beyond Meat

Carvana

Lamb Weston Hlds

Short holdings had a return of 30.8% in 2022 as the market slid.

Traders who bet against stocks made a killing in 2022, as short sellers netted $300 billion

Incyte

Inspire Medical Systems Inc

Schrodinger 

Veeva Systems

Verona Pharma

Viatris

With the healthcare sector poised to grow significantly in the coming years, healthcare stocks to buy present a fantastic opportunity for investors. Healthcare is something that everyone will need at some point in their lives, so today's industry of $8.3 trillion spent globally is an indication of a growing, profitable sector – one that could create many opportunities for those looking to make significant investments.

Why These 7 Healthcare Stocks Could Soar in 2023

Madrigal's lead drug candidate was already expected to be successful in its pivotal trial. FDA approval would then be earned by a positive on one of the trial's dual endpoints.

Madrigal Pharmaceuticals Setting The Standard

Potential suitors with heaps of cash to spend are lining up to get a closer look at this company's results.

This Stock That Tripled in 2022 Could Rocket Even Higher in 2023

Like an early Christmas/Hanukkah present, Madrigal shares rallied over 268% in one session due to the positive MAESTRO-NASH data. The shares continue to move in the ensuing day. Coupled with the strong Phase 3 (MAESTRO-NAFLD-1) results, Madrigal is poised to file a marketing application in H1 next year.

Madrigal Pharmaceuticals: Upcoming Windfall Profits

Biotech bulls stampeded the company following its latest clinical update.

Why Madrigal Pharmaceuticals Was a Top Stock This Week

Bionano Genomics

GlaxoSmithKline

iCAD

vTv Therapeutics

Choosing the best drug stocks to buy can be dicey because drug stocks have disadvantages and advantages. On the negative side, you often have to wait many years for promising drugs to prove themselves in clinical trials.

7 Drug Stocks That Will Soar in 2023

CONSHOHOCKEN, Pa., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that it has raised $259 million in gross equity (or $255 million in net proceeds) from equity securities issuances and an additional $50 million in liquidity commitments following the achievement of the clinical milestone under its Hercules Credit Facility.

Madrigal Pharmaceuticals Announces $300+ Million in Financing Events to Advance Resmetirom Program

News for Madrigal Pharmaceuticals Stock (MDGL)